Shenzhen Kaifa Technology
920029
Shanghai Yongli Belting
300230
Guomai Culture & Media
301052
WuHan Hvsen Biotechnology
300871
CHANGFU CO.,LTD
871396
CN Stock MarketDetailed Quotes
605507 Guobang Pharma Ltd.
- 21.00
- +0.37+1.79%
Market Closed Mar 28 15:00 CST
11.74BMarket Cap15.01P/E (TTM)
21.68High20.67Low131.37KlotVolume20.85Open20.63Pre Close278.56MTurnover4.35%Turnover Ratio15.01P/E (Static)558.82MShares23.0952wk High1.46P/B6.34BFloat Cap14.6552wk Low22.69Limit Up301.72MShs Float46.30Historical High18.57Limit Down4.90%Amplitude12.71Historical Low0.30Dividend TTM21.20Avg Price55.85KlotAsk1.44%Div YieldTTM100Lot Size64.61KlotBid
Guobang Pharma Ltd. Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 10.12%5.89B | 9.00%4.42B | 2.94%2.89B | -5.07%1.34B | -6.49%5.35B | -1.46%4.05B | 3.93%2.81B | 19.90%1.41B | 26.98%5.72B | 28.01%4.11B |
| Operating revenue | 10.12%5.89B | 9.00%4.42B | 2.94%2.89B | -5.07%1.34B | -6.49%5.35B | -1.46%4.05B | 3.93%2.81B | 19.90%1.41B | 26.98%5.72B | 28.01%4.11B |
| Other operating revenue | 6.70%23.85M | ---- | 96.15%14.62M | ---- | 28.96%22.35M | ---- | -6.10%7.45M | ---- | 39.43%17.33M | ---- |
| Total operating cost | 7.57%5.01B | 7.07%3.72B | 0.90%2.4B | -6.76%1.1B | -0.21%4.65B | 5.92%3.48B | 11.64%2.38B | 27.03%1.18B | 27.27%4.66B | 26.07%3.28B |
| Operating cost | 7.83%4.42B | 6.81%3.26B | 0.27%2.12B | -6.13%971.46M | -1.15%4.1B | 3.67%3.05B | 11.26%2.12B | 27.67%1.03B | 31.68%4.14B | 32.76%2.95B |
| Operating tax surcharges | 28.87%46.64M | 38.82%32.09M | 17.46%19.37M | -13.15%6.98M | 9.37%36.19M | 3.31%23.12M | 28.54%16.49M | 42.24%8.03M | 31.99%33.09M | 21.99%22.38M |
| Operating expense | 7.10%79.46M | -6.28%50.47M | -0.76%32.25M | 12.29%17.23M | 15.66%74.2M | 37.55%53.85M | 26.43%32.49M | 3.72%15.34M | 14.84%64.15M | -29.04%39.15M |
| Administration expense | -8.39%277.67M | -0.63%228.09M | -1.21%150.61M | -0.76%75.75M | 3.40%303.08M | 9.69%229.55M | 19.59%152.45M | 16.97%76.32M | 15.62%293.11M | 12.71%209.28M |
| Financial expense | 35.58%-29.82M | 81.44%-8.33M | 47.91%-21.1M | -469.45%-8.97M | 31.95%-46.28M | 33.54%-44.9M | -46.50%-40.51M | -289.42%-1.57M | -342.43%-68.01M | -424.60%-67.55M |
| -Interest expense (Financial expense) | 20.80%27.28M | 18.87%21.64M | 55.76%14.77M | 40.97%7.42M | 36.46%22.58M | 40.00%18.2M | 105.55%9.49M | 148.91%5.27M | -42.38%16.55M | -43.29%13M |
| -Interest Income (Financial expense) | 42.19%-29.94M | 40.54%-24.66M | 35.06%-19.4M | 34.73%-10.77M | -76.34%-51.78M | -138.81%-41.48M | -309.92%-29.87M | -444.03%-16.5M | -59.76%-29.36M | -75.00%-17.37M |
| Research and development | 12.88%215.05M | -1.52%160.29M | -4.60%92.96M | -19.64%37.65M | -3.56%190.51M | 20.51%162.76M | 12.51%97.44M | 48.02%46.86M | 27.22%197.54M | 27.16%135.06M |
| Credit Impairment Loss | -359.48%-12.25M | 31.77%-13.52M | -194.10%-13.88M | -72.58%-4.49M | 137.76%4.72M | -283.71%-19.81M | 33.58%-4.72M | 68.89%-2.6M | -1,258.59%-12.5M | -4,282.00%-5.16M |
| Asset Impairment Loss | 17.88%-25.83M | -4,234.47%-54.05M | -161.73%-44.54M | -764.96%-8.83M | -13.50%-31.45M | 87.26%-1.25M | -114.23%-17.02M | 87.08%-1.02M | 46.54%-27.71M | 53.28%-9.79M |
| Other net revenue | 48.62%11.35M | -78.89%-19.58M | -38.65%-22.69M | -1,030.25%-2.5M | 332.98%7.64M | -197.41%-10.95M | -606.56%-16.37M | 103.49%268.79K | 89.49%-3.28M | 202.61%11.24M |
| Fair value change income | 39.26%14.4M | --10.14M | 59.77%5.81M | ---380.32K | 126.89%10.34M | ---- | --3.64M | ---- | -27.15%4.56M | ---- |
| Invest income | -2.06%12.95M | 145.14%11.45M | 811.66%10.28M | 214.11%7.27M | -32.33%13.22M | -75.50%4.67M | -111.51%-1.44M | -61.50%2.31M | 356.92%19.54M | 1,832.38%19.07M |
| -Including: Investment income associates | -4,750.82%-2.81M | 14.93%-1.3M | -57.78%-453.32K | -70.06%-695.27K | 108.12%60.46K | -75.65%-1.53M | 63.42%-287.31K | 18.70%-408.83K | 52.29%-744.63K | -46.54%-871.48K |
| Asset deal income | ---9.11M | --2.26K | --2.26K | ---- | ---- | ---- | ---- | ---- | -99.99%44.63 | ---- |
| Other revenue | 188.71%31.18M | 385.33%26.39M | 517.73%19.64M | 149.33%3.94M | -15.87%10.8M | -23.60%5.44M | -44.48%3.18M | -38.35%1.58M | 19.62%12.84M | -17.96%7.12M |
| Operating profit | 27.45%895.07M | 19.50%673.95M | 13.16%472.46M | 2.41%236.11M | -33.30%702.26M | -32.89%563.98M | -27.84%417.52M | -3.77%230.55M | 30.18%1.05B | 40.74%840.33M |
| Add:Non operating Income | 12.83%3.74M | 62.30%3.44M | 589.25%2.6M | 113.16%482.07K | 489.23%3.32M | 127.98%2.12M | -35.51%377.86K | -30.73%226.15K | -94.18%562.61K | -90.75%928.6K |
| Less:Non operating expense | 36.67%10.84M | 94.90%12.75M | 120.03%10.97M | 19.60%2.56M | -55.45%7.93M | -39.56%6.54M | -54.94%4.99M | -55.44%2.14M | 52.67%17.8M | 79.46%10.82M |
| Total profit | 27.28%887.97M | 18.78%664.63M | 12.40%464.09M | 2.36%234.02M | -32.64%697.65M | -32.62%559.55M | -27.32%412.91M | -2.75%228.63M | 28.37%1.04B | 38.16%830.44M |
| Less:Income tax cost | 22.50%107.39M | 19.61%85.99M | 6.55%59.72M | 5.30%35.44M | -23.78%87.67M | -34.09%71.89M | -23.37%56.05M | -3.26%33.66M | 14.39%115.02M | 37.32%109.08M |
| Net profit | 27.97%780.58M | 18.66%578.64M | 13.31%404.37M | 1.85%198.58M | -33.74%609.98M | -32.40%487.66M | -27.91%356.86M | -2.66%194.97M | 30.36%920.62M | 38.28%721.36M |
| Net profit from continuing operation | 27.97%780.58M | 18.66%578.64M | 13.31%404.37M | 1.85%198.58M | -33.74%609.98M | -32.40%487.66M | -27.91%356.86M | -2.66%194.97M | 30.36%920.62M | 38.28%721.36M |
| Less:Minority Profit | 59.04%-1.02M | 82.59%-246.74K | 62.74%-228.91K | -144.57%-152.44K | -780.84%-2.49M | -586.07%-1.42M | -1,318.46%-614.41K | 488.30%342.02K | -241.63%-282.17K | -48.41%291.63K |
| Net profit of parent company owners | 27.61%781.6M | 18.36%578.88M | 13.18%404.6M | 2.11%198.73M | -33.49%612.46M | -32.17%489.07M | -27.79%357.47M | -2.88%194.63M | 30.43%920.9M | 38.38%721.06M |
| Earning per share | ||||||||||
| Basic earning per share | 27.27%1.4 | 18.18%1.04 | 14.06%0.73 | 2.86%0.36 | -33.33%1.1 | -31.78%0.88 | -28.09%0.64 | -2.78%0.35 | 19.57%1.65 | 21.70%1.29 |
| Diluted earning per share | 27.27%1.4 | 18.18%1.04 | 14.06%0.73 | 2.86%0.36 | -33.33%1.1 | -31.78%0.88 | -28.09%0.64 | -2.78%0.35 | 19.57%1.65 | 21.70%1.29 |
| Other composite income | ||||||||||
| Total composite income | 27.97%780.58M | 18.66%578.64M | 13.31%404.37M | 1.85%198.58M | -33.74%609.98M | -32.40%487.66M | -27.91%356.86M | -2.66%194.97M | 30.36%920.62M | 38.28%721.36M |
| Total composite income of parent company owners | 27.61%781.6M | 18.36%578.88M | 13.18%404.6M | 2.11%198.73M | -33.49%612.46M | -32.17%489.07M | -27.79%357.47M | -2.88%194.63M | 30.43%920.9M | 38.38%721.06M |
| Total composite income of minority owners | 59.04%-1.02M | 82.59%-246.74K | 62.74%-228.91K | -144.57%-152.44K | -780.84%-2.49M | -586.07%-1.42M | -1,318.46%-614.41K | 488.30%342.02K | -241.63%-282.17K | -48.41%291.63K |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
